The convergence of advancements in precision medicine, biomarker elucidation, drug delivery modalities, and an enriched comprehension of NF-κB’s intricate roles in AD pathogenesis is poised to catalyze the successful transition of this strategy from preclinical research to efficacious clinical treatments. The gene discussed is NFKB1; the disease is Alzheimer disease.